Related references
Note: Only part of the references are listed.Summary From the First Kidney Cancer Research Summit , September 12-13, 2019: A Focus on Translational Research
Toni K. Choueiri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
Sumanta K. Pal et al.
LANCET (2021)
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma
Thomas E. Hutson et al.
EUROPEAN UROLOGY (2021)
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study
Sumanta K. Pal et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
Bradley A. McGregor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Amin H. Nassar et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
Martin H. Voss et al.
BRITISH JOURNAL OF CANCER (2020)
Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer
Praful Ravi et al.
CANCER JOURNAL (2020)
Tissue Based Biomarkers for Metastatic Clear Cell Renal Carcinoma: A Systematic Review
Andrew L. Schmidt et al.
KIDNEY CANCER (2020)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial
Martin H. Voss et al.
CLINICAL CANCER RESEARCH (2019)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phosphatase and tensin homolog (PTEN) expression on oncologic outcome in renal cell carcinoma: A systematic review and meta-analysis
Lu Tang et al.
PLOS ONE (2017)
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
J. J. Knox et al.
ANNALS OF ONCOLOGY (2017)
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
David J. Kwiatkowski et al.
CLINICAL CANCER RESEARCH (2016)
f Institutional implementation of clinical tumor profiling on an unselected cancer population
Lynette M. Sholl et al.
JCI INSIGHT (2016)
Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: Results of a pooled analysis of non-interventional studies
Laurence Albiges et al.
EUROPEAN JOURNAL OF CANCER (2015)
Oncotator: Cancer Variant Annotation Tool
Alex H. Ramos et al.
HUMAN MUTATION (2015)
Comprehensivemolecular characterization of clear cell renal cell carcinoma
Chad J. Creighton et al.
NATURE (2013)
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Kristian Cibulskis et al.
NATURE BIOTECHNOLOGY (2013)
mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin
Seong A. Kang et al.
SCIENCE (2013)
Rapamycin passes the torch: a new generation of mTOR inhibitors
Don Benjamin et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
A method and server for predicting damaging missense mutations
Ivan A. Adzhubei et al.
NATURE METHODS (2010)
Fast and accurate short read alignment with Burrows-Wheeler transform
Heng Li et al.
BIOINFORMATICS (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Common corruption of the mTOR signaling network in human tumors
S Menon et al.
ONCOGENE (2009)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
mTOR and cancer: insights into a complex relationship
David M. Sabatini
NATURE REVIEWS CANCER (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
SIFT: predicting amino acid changes that affect protein function
PC Ng et al.
NUCLEIC ACIDS RESEARCH (2003)
Share Paper
